Abstracts tagged "Psoriatic arthritis"

Abstract Number: L03 • ACR Convergence 2020
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Jonghyeon Kim⁶, Shalabh Singhal⁶, Miroslawa Nowak⁶ and Subhashis Banerjee⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Leiden University Medical Center, Leiden, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signaling by key cytokines involved in psoriatic arthritis (PsA) pathophysiology. Deucravacitinib (BMS-986165) is a…
Abstract Number: 0155 • ACR Convergence 2020
Changes in Patient-Reported Outcome (PRO) Scores for Nausea and Fatigue Following Weekly Methotrexate Dose in a Real-World Sample of RA and PsA Patients in the ArthritisPower Registry
William Nowell¹, Elaine Karis², Kelly Gavigan³, Laura Stradford³, Scott Stryker², Huifeng Yun⁴, Shilpa Venkatachalam⁵, Gregory Kricorian², Lang Chen⁴, Hong Zhao⁶, Fenglong Xie⁶ and Jeffrey R Curtis⁴, ¹Global Healthy Living Foundation, New York City, NY, ²Amgen Inc., Thousand Oaks, CA, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is frequently used in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) because of its beneficial effects in both populations. Despite…
Abstract Number: 0314 • ACR Convergence 2020
Accuracy of Physical Examination to Detect Synovial and Extra-synovial Pathologies in Psoriatic Arthritis in Comparison to Ultrasonography
Ummugulsum Gazel¹, Dilek Solmaz², Gizem Ayan³, Catherine Ivory⁴, Jacob Karsh⁴ and Sibel Aydin⁵, ¹University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, ottawa, Canada, ²Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, TURKEY, Izmir, Turkey, ³University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA, Ottawa Hospital Research Institute, OTTAWA, ON, Canada, ⁴University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA, Ottawa, ON, Canada, ⁵University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada
Background/Purpose: The aim of this study to explore the comparison of physical examination (PE) and ultrasound (US) detected synovial and extra-synovial pathologies of the hands…
Abstract Number: 0330 • ACR Convergence 2020
Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors
Timothy Kwok¹, Mitchell Sutton², Daniel Pereira², Vinod Chandran³ and Dafna Gladman³, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Despite optimal medical therapy, joint space disease and skeletal damage persists in a subset of patients with PsA, many of whom requiring musculoskeletal (MSK)…
Abstract Number: 0349 • ACR Convergence 2020
Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year
Christopher Ritchlin¹, Proton Rahman², Philip Helliwell³, Wolf-Henning Boehncke⁴, Iain McInnes⁵, Alice Gottlieb⁶, Shelly Kafka⁷, Alexa Kollmeier⁸, Elizabeth Hsia⁹, Xie Xu¹⁰, May Shawi¹¹, Shihong Sheng¹², Prasheen Agarwal¹², Bei Zhou¹², Paraneedharan Ramachandran¹³ and Philip Mease¹⁴, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ¹⁰Janssen Research & Development, LLC, San Marcos, CA, ¹¹Janssen Global Services, LLC, Toronto, ON, Canada, ¹²Janssen Research & Development, LLC, Spring House, PA, ¹³Janssen Research & Development, LLC, Horsham, ¹⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2, two double-blind, phase 3, psoriatic arthritis (PsA) trials of guselkumab (GUS, an IL-23 inhibitor), demonstrated significant improvement with GUS vs…
Abstract Number: 0377 • ACR Convergence 2020
Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Lihi Eder¹, Dafna Gladman², Sibel Zehra Aydin³, Alexis Ogdie⁴, Harry Shi⁵, Pierre-Alexandre Landry⁶ and Rayana Luna⁶, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada, ⁴Division of Rheumatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Canada ULC, Kirkland, Canada
Background/Purpose: Studies indicate that sex (male vs female) is predictive of outcomes with PsA treatments, such as TNF inhibitors (TNFi).1 Tofacitinib is an oral JAK…
Abstract Number: 0548 • ACR Convergence 2020
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up
Maria Auxiliadora Martin-Martinez¹, Santos Castañeda², Fernando Sanchez-Alonso³, Carmen García-Gómez⁴, Carlos González_Juanatey⁵, M. Ángeles Belmonte-López⁶, Jesus Tornero-Molina⁷, José Santos-Rey⁸, Carmen Olga Sánchez-González⁹, Estefania Moreno¹⁰, Maria del puerto Moreno-Gil¹¹, Tatiana Cobo-Ibañez¹², Jose Antonio Pinto-Tasende¹³, Jesús Babío-Herráez¹⁴, Gema Bonilla¹⁵, Antonio Juan-Mas¹⁶, Francisco Manero-Ruiz¹⁷, Montserrat Romera-Baurés¹⁸, Javier Bachiller-Corral¹⁹, Eugenio Chamizo-Carmona²⁰, Javier Calvo-Catalán²¹, Raimon Sanmartí²², Celia Erausquin-Arruabarrena²³, Rosario Garcia-Vicuña²⁴, Carmen Barbadillo²⁵, Sergio Ros-Expósito²⁶, Ana Isabel Turrión²⁷, M José González-Fernández²⁸, Jose Miguel Senabre²⁹, Silvia Martínez-Pardo³⁰, Ana Ruibal-Escribano³¹, Emilio Giner-Serret³², Elisabet Berzosa-Sola³³, Julia Martínez-Barrio³⁴, Encarnación Pagán³⁵, M Enriqueta- Peiró³⁶, Sagrario Bustabad-Reyes³⁷, Alba Erra-Durán³⁸, Beatriz González Álvarez³⁹, Ana Cruz Valenciano⁴⁰, Javier Rivera-Redondo⁴¹, Manuel Moreno Ramos⁴², Sergio Rodriguez Montero⁴³, Mercedes Morcillo-Valle⁴⁴, Maria Teresa Navío⁴⁵, Maria Galindo-Izquierdo⁴⁶, Manuel Riera-Soler⁴⁷, Jordi Fiter⁴⁸, Javier Llorca⁴⁹ and Miguel Ángel González-Gay⁵⁰, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ⁴Consorci Sanitari de Terrassa, Barcelona, Spain, ⁵Hospital Lucus Augusti, Lugo, Spain, ⁶Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁷University Hospital of Guadalajara. Spain, Madrid, Madrid, Spain, ⁸Hospital Virgen de la Salud, Toledo, Spain, ⁹Hospital Sureste, Madrid, Spain, ¹⁰Universitario Vall D'hebron, Barcelona, Spain, ¹¹Complejo Hospitalario de Cáceres, Caceres, Spain, ¹²Hospital Infanta Sofia, Madrid, Spain, ¹³CHUAC, A Coruña, Spain, ¹⁴Hospital de Cabueñes, Gijón, Spain, ¹⁵Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ¹⁶Hospital Sont Llatzer, Palma de Mallorca, Spain, ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁰Hospital de Merida, Badajoz, Spain, ²¹Hospital General Universitario Valencia, Valencia, Spain, ²²Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ²³Hospital de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ²⁴Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Viladecans, Barcelona, Spain, ²⁷Hospital Universitario de Salamanca, Salamanca, Spain, ²⁸Hospital Dexeus, Barcelona, Spain, ²⁹Hospital de Marina Baixa, Alicante, Spain, ³⁰H. Mutua de Terrassa, Barcelona, Catalonia, Spain, ³¹Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ³²Hospital Obispo Polanco, Teruel, Spain, ³³Hospital del Elda, Alicante, Spain, ³⁴Hospital General Universitario Gregorio Marañón, Madrid, ³⁵Hospital Los Arcos, Murcia, Spain, ³⁶Hospital Marques de Valdecilla, Santander, Spain, ³⁷Hospital Universitario Canarias, Tenerife, Spain, ³⁸Hospital San Rafael, Barcelona, Spain, ³⁹Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, ⁴⁰Hospital Severo Ochoa, Madrid, Spain, ⁴¹Instituto Provincial de Rehabilitación, Madrid, Spain, ⁴²Hospital Virgen de la Arrixaca, Murcia, Spain, ⁴³H. Virgen de Valme, Sevilla, Spain, ⁴⁴Hospital El Escorial, Madrid, Spain, ⁴⁵Hospital Infanta Leonor, Madrid, Spain, ⁴⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴⁷Hospital dos de Maig, Barcelona, Spain, ⁴⁸Hospital Universitario Son Dureta, Palma de Mallorca, Spain, ⁴⁹School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵⁰Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular (CV) event (CVE) in patients with chronic inflammatory rheumatic diseases…
Abstract Number: 0902 • ACR Convergence 2020
Impact of Dose Escalation of Secukinumab in Patients with Psoriatic Arthritis in Real-World Setting
Maria Martin-Lopez¹, Beatriz Joven² and Jose Luis Pablos¹, ¹Hospital 12 de Octubre, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Madrid, Spain
Background/Purpose: Secukinumab (SEC) has provided efficacy in clinical trials in patients with psoriatic arthritis (PsA). In PsA patients, a gain in response has been suggested…
Abstract Number: 1318 • ACR Convergence 2020
Catastrophizing in Patients with Axial Spondyloarthritis and Psoriatic Arthritis
Baptiste Coste¹, Charlotte Traverson¹, Elisabeth Filhol¹, Soraya Benamar¹, Jacques Morel², Sabine Laurent-Chabalier³, Bernard Combe⁴, Claire Daien², Cédric Lukas⁵, Charlotte Hua¹ and Cecile Gaujoux-Viala⁶, ¹Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, Nimes, France, ²Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ³Department of Biostatistics, Clinical Epidemiology, Public Health and innovation in Methodology, CHU Nîmes, University of Montpellier-Nîmes, France, Nimes, France, ⁴University of Montpellier, Montpellier, France, ⁵CHU Montpellier and University of Montpellier, Montpellier, France, ⁶Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France
Background/Purpose: Catastrophizing is a negative cognitivo-affective response to an anxiety-provoking stimulus, especially to pain. Catastrophism plays a role in maintaining chronic pain and is associated…
Abstract Number: 1352 • ACR Convergence 2020
Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
Joseph Merola¹, Frank Behrens², Alan Kivitz³, Philip Mease⁴, Iain McInnes⁵, Barbara Ink⁶, Deepak Assudani⁷, Paulatsya Joshi⁷, Jason Coarse⁸ and Christopher Ritchlin⁹, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ³Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁵Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶UCB Pharma, Slough, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Raleigh, NC, ⁹Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes over…
Abstract Number: 1543 • ACR Convergence 2020
Prevalence of Ultrasound Findings Suggestive of Inflammatory Arthritis in Children with Skin Psoriasis (ChildEchoPso)
Luis Coronel¹, Tania Gudu², Sophie Ruel-Gagné¹, Helen Gouze³, Francois Vidal⁴, Ilaria Padovano⁴, Felice Constantino², Maxime Breban⁴, Emmanuel Mahe⁵ and Maria Antonietta D'Agostino⁶, ¹Hôpital Ambroise-Paré, Boulogne-Billancourt, France, ²Hôpital Ambroise-Paré, Bolougne-Billancourt, France, ³[email protected], Bolougne-Billancourt, France, ⁴Hôpital Ambroise-Paré, Bolougne-Billancourt, ⁵Centre Hospitalier Victor Dupouy, Argenteuil, France, ⁶Paris-Saclay Versailles University, Hôpital Ambroise Paré, Boulogne-Billancourt, France
Background/Purpose: The prevalence of psoriasis in children is estimated between 0.5-1% (1), and can be associated with musculoskeletal involvement, althought the prevalence and typology of…
Abstract Number: 2015 • ACR Convergence 2020
Prevalence and Distribution of Peripheral Musculoskeletal Manifestations in Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis: Results of the International, Cross-sectional ASAS-PerSpA Study
Clementina Lopez-Medina¹, Anna Molto¹, Joachim Sieper², Mehmet Tuncay Duruöz³, Uta Kiltz⁴, Bassel El-Zorkany⁵, Najia Hajjaj-Hassouni⁶, Ruben Burgos-Vargas⁷, Jose Maldonado-Cocco⁸, Nelly Ziade⁹, Meghna Gavali¹⁰, Victoria Navarro-Compán¹¹, Shue Fen Luo¹², Sara Monti¹³, Tae-Jong Kim¹⁴, Mitsumasa Kishimoto¹⁵, Fernando Pimentel-Santos¹⁶, Jieruo Gu¹⁷, Ruxandra Schiotis¹⁸, Floris van Gaalen¹⁹, Pál Géher²⁰, Marina Magrey²¹, Sebastian Ibanez²², Wilson Bautista-Molano²³, Walter Maksymowych²⁴, Pedro M Machado²⁵, Robert Landewé²⁶, Désirée van der Heijde²⁷ and Maxime Dougados²⁸, ¹Rheumatology Department, Cochin Hospital, Paris, Paris, France, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey, ⁴Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁵Cairo University, Cairo, Egypt, ⁶Health Sciences College, International University of Rabat (UIR), Rabat, Morocco, ⁷Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ⁸Buenos Aires School of Medicine, Buenos Aires, Argentina, ⁹Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ¹⁰Nizam’s Institute of Medical Sciences, Hyderabad, India, ¹¹Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ¹²Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), ¹³Fondazione IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy, ¹⁴Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ¹⁵Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ¹⁶3.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisbon, Portugal, ¹⁷Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, guangzhou, China (People's Republic), ¹⁸Pharmacology Department Department, Iuliu Hatieganu University of Medicine and Pharmacy, SCBI-Rheumatology Department, Cluj-Napoca, Romania, ¹⁹Leiden University Medical Center (LUMC), Leiden, Netherlands, ²⁰Semmelweis University, Budapest, Hungary, ²¹Case Western Reserve University School of Medicine, Cleveland, OH, ²²Facultad de Medicina Clínica Alemana – Universidad del Desarrollo, Santiago, Region Metropolitana, Chile, ²³University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia, ²⁴University of Alberta, Edmonton, AB, Canada, ²⁵University College London, London, United Kingdom, ²⁶Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ²⁷Leiden University Medical Center, Leiden, Netherlands, ²⁸Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France
Background/Purpose: Peripheral musculoskeletal manifestations in patients with Psoriatic Arthritis (PsA) have been widely studied. However, there is a lack of knowledge on the distribution of…
Abstract Number: 0160 • ACR Convergence 2020
Use of PROMIS29 Across Inflammatory Arthritis: Score Distributions and Impact of Contextual Factors
Alexis Ogdie¹, Kaleb Michaud², Mark Hwang³, Sofia Pedro⁴ and Patricia Katz⁵, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita, ³McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵University of California, San Francisco, Novato, CA
Background/Purpose: The Patient-Reported Outcome Measure Information System (PROMIS) includes a set of instruments developed to measure physical, mental and social health. PROMIS measures have been…
Abstract Number: 0315 • ACR Convergence 2020
The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia
Ari Polachek¹, Victoria Furer², Mirna Zureik³, Sharon Nevo³, Liran Mendel⁴, David Levartovsky², Jonathan Wollman³, Valerie Aloush², Mark Berman², Ilana Kaufman⁵, Reut Tzemach⁴, Marina Anouk⁶, Ofir Elalouf⁷, Hagit Padova⁴, Or Carmi⁸, Tali Eviatar⁹, Yael Lahat goldstein², Hagit Sarbagil-Maman¹⁰, Sara Borok Lev-Ran², Adi Broide³, Lihi Eder¹¹, Daphna Paran² and Ori Elkayam³, ¹Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁴Souraaky Medical Center, Tel-Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Petah-Tiqwa, Israel, ⁶Souraaky Medical Center, Tel Aviv, Israel, ⁷Souraaky Medical Center, Herzliya, Israel, ⁸Souraaky Medical Center, herzelia, Israel, ⁹Tel Aviv Sourasky Medical Center, Givataim, Israel, ¹⁰Tel-Aviv Sourasky Medical Center, Kiryat Ono, Israel, ¹¹University of Toronto, Toronto, ON, Canada
Background/Purpose: The presence of fibromyalgia (FMS) in psoriatic arthritis (PsA) patients increases the scores of the clinical measures of disease activity. The aim of this…
Abstract Number: 0331 • ACR Convergence 2020
Work Absenteeism and Disability Associated with Psoriatic Arthritis and Psoriasis in the United States – A Retrospective Study of Claims Data from 2009 to 2020
Ana-Maria Orbai¹, Soumya Reddy², Steven Peterson³, Natalie Dennis⁴, Reginald Villacorta⁵, Laura Mesana⁶, Soumya Chakravarty⁷, Maud Pacou⁴, Iris Lin⁵, Thomas Baker⁸, Yiting Wang⁹ and Jessica Walsh¹⁰, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²NYU School of Medicine, New York City, ³Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁴Amaris, Paris, France, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Amaris, New York, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁸Janssen Global Services, LLC, Raritan, NJ, ⁹Janssen R&D, LLC, Titusville, ¹⁰University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Absenteeism and work disability substantially contribute to the economic burden of psoriasis and psoriatic arthritis (PsA). This study compared work absenteeism and short-term disability…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].